Home・Lista de Ações・Natera Inc

Natera Inc

Fechado

SetorSaúde

321.98 21.19

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

265.23

Máximo

321.98

Indicadores-chave
By Trading Economics
Rendimento	-132M -85M
Vendas	31M 697M
EPS	-0.6
Margem de lucro	-12.214
Funcionários	6,135
EBITDA	-30M -65M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+19.94% upside

Dividendos
By Acuity
Próximos Ganhos	5 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	8.5B 39B
Abertura anterior	300.79
Fecho anterior	321.98

Sentimento de Notícias

By Acuity

40%

60%

120 / 340 Ranking em Healthcare

Natera Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2026, 20:03 UTC

Social Media

News

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.

6 de ago. de 2026, 23:02 UTC

Social Media

News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5 de ago. de 2026, 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4 de ago. de 2026, 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3 de ago. de 2026, 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31 de jul. de 2026, 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30 de jul. de 2026, 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

29 de jul. de 2026, 22:02 UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

28 de jul. de 2026, 23:46 UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

27 de jul. de 2026, 19:46 UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

24 de jul. de 2026, 18:46 UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

22 de jul. de 2026, 18:36 UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

21 de jul. de 2026, 18:36 UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

20 de jul. de 2026, 18:16 UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Comparação entre Pares

Variação de preço

Natera Inc Previsão

Preço-alvo

By TipRanks

19.94% parte superior

Previsão para 12 meses

Média 318.29 USD 19.94%

Máximo 375 USD

Mínimo 249 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Natera Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

Comprar

Manter

Vender

Com base em 19 analistas que deram avaliações de ações para Natera Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

120 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.